Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 19/20 | 0.71 |
| ▸ | CD63 | P08962 | 5/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | ROS1 | P08922 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.46 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15552545 | 1.00 | SYK (0.71) | SYKCD63AURKAJAK2NTRK1 | |
| SCHEMBL15552542 | 1.00 | SYK (0.71) | SYKCD63AURKAJAK2NTRK1 | |
| SCHEMBL15552238 | 0.93 | SYK (0.62) | SYKCD63AURKAJAK2NTRK1 | |
| SCHEMBL15552563 | 0.89 | SYK (0.66) | SYKCD63AURKAJAK2NTRK1 | |
| SCHEMBL15552562 | 0.89 | SYK (0.66) | SYKCD63AURKAJAK2NTRK1 | |
| SCHEMBL20344867 | 0.85 | SYK (0.53) | SYKCD63AURKAJAK2 | |
| SCHEMBL15552279 | 0.85 | SYK (0.53) | SYKCD63AURKAJAK2NTRK1 | |
| SCHEMBL15552276 | 0.85 | SYK (0.53) | SYKCD63AURKAJAK2NTRK1 | |
| SCHEMBL20005722 | 0.83 | AURKA (0.65) | SYKCD63AURKAJAK2NTRK1 | |
| SCHEMBL16820582 | 0.83 | SYK (1.00) | SYKCD63AURKAJAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12263163-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor | Kronos Bio, Inc. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | GILEAD SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | GILEAD SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | GILEAD SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11517570-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | Kronos Bio, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
| EP-3342773-B9 | SYK INHIBITORS | KRONOS BIO INC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3342773-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2020-11-11 | — | — | EP | disclosed |
| US-9968601-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9931338-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3087075-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016172117-A1 | TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160310490-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-10-27 | — | — | US | disclosed |
| US-20160310490-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-10-27 | — | — | US | disclosed |
| US-9290505-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290505-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160058758-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-20160058758-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-03-03 | — | — | US | disclosed |
| WO-2015100217-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20150175616-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-06-25 | — | — | US | disclosed |
| US-20150175616-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517570-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | SYK, LCK, LYN | SYK 1/4885CD63 3157/4885AURKA 308/4885 |
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | SYK, LCK, LYN | SYK 1/4885CD63 3157/4885AURKA 308/4885 |
| US-12263163-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor | SYK, LCK, LYN | SYK 1/4885CD63 3342/4885AURKA 325/4885 |
| US-20150175616-A1 | SYK INHIBITORS | SYK, BTK, LYN | SYK 1/4885CD63 2113/4885AURKA 711/4885 |
| US-20160310490-A1 | SYK INHIBITORS | SYK, BTK, LYN | SYK 1/4885CD63 2113/4885AURKA 711/4885 |
| US-20160058758-A1 | SYK INHIBITORS | SYK, BTK, LYN | SYK 1/4885CD63 2809/4885AURKA 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.